Retatrutide: what the Phase 2 and Phase 3 trials have actually measured

In plain English

Retatrutide is an investigational drug — still in large-scale clinical trials, not yet approved anywhere — being studied primarily for obesity and type 2 diabetes. Unlike earlier weight-loss medicines, it activates three hormone receptors at once instead of one or two. Those three receptors (GIP, GLP-1, and glucagon) each play a different role in how the body handles hunger and energy. Activating all three at the same time appears to produce larger weight reductions than any single-target approach measured so far.

In a 48-week Phase 2 trial, the highest studied dose produced a mean weight loss of about 24% — roughly one in four pounds lost. That figure comes from a randomized controlled trial, not anecdote. The compound is developed by Eli Lilly under the name LY3437943 and is currently in Phase 3 trials branded TRIUMPH.

This site summarizes the published literature on retatrutide — how it works, what the trials measured, and what the side-effect and safety record shows. What people in research-use communities report — including the downsides — is on the effects page. This is a literature digest, not a clinic and not a vendor.

What the retatrutide trials have measured

Retatrutide is a 39-amino-acid synthetic peptide engineered to activate three receptors simultaneously: the GLP-1 receptor (glucagon-like peptide-1, an incretin hormone that slows gastric emptying and suppresses appetite), the GIP receptor (glucose-dependent insulinotropic polypeptide, which enhances post-meal insulin secretion and influences fat-tissue metabolism), and the glucagon receptor (a pancreatic hormone that raises blood glucose and, when activated with the other two receptors in balance, increases energy expenditure and hepatic lipid breakdown). This combination is called a triple agonist.

The largest Phase 2 data point: a 48-week randomized controlled trial in 338 adults with obesity found that once-weekly subcutaneous retatrutide at 12 mg produced a mean body-weight change of −24.2%, compared with −2.1% in the placebo group ^[1]. That is the headline number from which Retatrutide research derives.

A parallel Phase 2 trial in 281 adults with type 2 diabetes found that 12 mg lowered HbA1c (glycated hemoglobin, a three-month average blood-glucose marker) by −2.02 percentage points at 24 weeks and reduced body weight by −16.94% at 36 weeks ^[2].

A first-in-human Phase 1b study established a half-life of approximately 6 days, supporting once-weekly dosing, and showed placebo-adjusted weight loss of −8.96 kg at the highest dose over 12 weeks ^[4].

The triple-agonist mechanism

To understand why retatrutide produces larger weight reductions than earlier incretin agents, it helps to understand what each of the three receptor arms does separately — and why combining all three in one molecule matters.

GLP-1 receptor agonism slows gastric emptying (the rate food leaves the stomach), reduces appetite signaling in the brain, and stimulates insulin secretion in a glucose-dependent way — meaning it amplifies insulin release when blood sugar is elevated but not when it is already low. GIP receptor agonism complements this with additional insulinotropic and adipose-tissue effects. These two together are the mechanism of the dual-agonist class. Retatrutide adds a third arm: glucagon-receptor activation, which increases energy expenditure by driving thermogenesis (heat production from stored fuel) and accelerates hepatic (liver) lipid metabolism — effectively asking the body to burn more fuel even at rest.

A 2025 mechanistic review synthesizes how these three pathways interact: the glucagon arm appears to add energy-expenditure drive that neither GLP-1 nor GIP agonism alone can supply, and the combination produces greater weight reduction than either component in isolation ^[9]. Structural cryo-EM studies have resolved how the single retatrutide molecule physically docks into all three receptor pockets simultaneously ^[3]. How does retatrutide work walks through this mechanism in full.

Liver fat and metabolic effects beyond weight

One of the more striking data points in the retatrutide record is its effect on liver fat. In a 48-week Phase 2 substudy in participants with obesity and MASLD (metabolic dysfunction-associated steatotic liver disease, the current term for fatty liver linked to metabolic risk factors), 12 mg reduced liver fat by −82.4% at 24 weeks by MRI-PDFF (magnetic resonance imaging proton density fat fraction, a non-invasive measure of liver fat content), with 86% of participants reaching a normal liver-fat fraction below 5% ^[5]. The effect was sustained at 48 weeks (−86.0% at 12 mg).

A 2025 study characterized how retatrutide affects appetite, eating attitudes, and eating behavior during treatment ^[8]. In qualitative exit interviews with Phase 2 trial participants, 31 of 36 retatrutide-treated subjects reported changes in eating behavior within the first 8 weeks, including reduced hunger frequency, greater satiety, smaller portions, altered food preferences, and a greater sense of control over eating ^[10].

What does retatrutide do

At the level of mechanism: retatrutide activates three hormone receptors at once, suppressing appetite, improving glucose metabolism, and increasing energy expenditure. At the level of trial outcomes: it produced the largest weight reductions of any pharmacological agent measured in a randomized controlled trial as of the time of its Phase 2 publication — up to −24.2% at 48 weeks in the obesity trial ^[1] and −16.94% at 36 weeks in the diabetes trial ^[2].

A 2025 narrative review characterized the up-to-~24% weight loss from Phase 2 data as a step-change relative to earlier incretin therapies ^[6]. That characterization is careful: it describes what the Phase 2 data showed, not what a marketed drug has been proven to deliver at scale in a real-world population. Phase 3 TRIUMPH trials are ongoing; no approval has been granted.

Retatrutide is not FDA-approved and not available as a prescription product. It does not currently treat or cure any condition in a regulatory sense. It is an investigational molecule studied in controlled clinical trials, the results of which are summarized on this site.